Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
PMV Pharma is developing first-in-class p53 regulators for the treatment of cancer. PMV Pharma combines unique biological understanding with pharmaceutical development focus.
News
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants PMVP Stock News
PMV Pharmaceuticals announced a public offering of 22 million shares and 19 million pre-funded warrants, aiming for $50.8 million in proceeds.Quiver AI SummaryPMV Pharmaceuticals, Inc. announced the pricing of an underwritten public offering that includes
Read more
Report
PMV Pharma Announces Proposed Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (
Read more
Report
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 monthsRecent FDA interaction supports...
Read more
Report
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical...
Read more
Report
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair...
Read more
Report
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian...
Read more
Report
PMV Pharmaceuticals, Inc. (PMVP) stock price, news, quote and history - Yahoo Finance
Find the latest PMV Pharmaceuticals, Inc. (PMVP) stock quote, history, news and other vital information to help you with your stock trading and investing.
Read more
Report
